BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16870435)

  • 1. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.
    Li YL; Fevig JM; Cacciola J; Buriak J; Rossi KA; Jona J; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5176-82. PubMed ID: 16870435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
    Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
    Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
    [No Abstract]   [Full Text] [Related]  

  • 4. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
    Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
    Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
    J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
    Pandya V; Jain M; Chakrabarti G; Soni H; Parmar B; Chaugule B; Patel J; Jarag T; Joshi J; Joshi N; Rath A; Unadkat V; Sharma B; Ajani H; Kumar J; Sairam KV; Patel H; Patel P
    Eur J Med Chem; 2012 Dec; 58():136-52. PubMed ID: 23124211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
    Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
    J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
    Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
    ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
    Ueno H; Katoh S; Yokota K; Hoshi J; Hayashi M; Uchida I; Aisaka K; Hase Y; Cho H
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4281-6. PubMed ID: 15261287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
    J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
    Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Czech J; Lorenz M; Laux V; Wehner V
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4197-201. PubMed ID: 15261269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.
    Haginoya N; Kobayashi S; Komoriya S; Hirokawa Y; Furugori T; Nagahara T
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2935-9. PubMed ID: 15125963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.